LETTER FROM EDITOR-IN-CHIEF

“Never let useful medical research data go unpublished”

It is my privilege to introduce our readers to a unique and very exceptional new journal: The Journal of Unexplored Medical Data (JUMD). JUMD explores unpublished data in the field of medical biology, therapy, immunotherapy and cancer prevention/epidemiology.

Every year academic educational institutes produce more data in medical research than they are able to publish. It is evident that not all research work produces publishable output, consequently ample amounts of useful medical data never emerges from the hard drive of the labs which produced it. No doubt that while there are batches of 'flotsam and jetsam' that nobody wants to see there is also a lot of perfectly fine data going unpublished that would help other investigators out. Lack of funds, facilities or even expertise to complete work to a publishable standard in the traditional journals could be some of the reasons why so much research goes unpublished. As a result a wealth of scientific data, hard work and funding is wasted.

Traditional journals fail to provide a specific platform for such large datasets of unpublished work that could benefit a wider research community and are possibly essential for efficient scientific progress. For that reason, JUMD, has been launched to rescue a great wealth of valuable unpublished cancer biological and medical data.

JUMD is an exceptional peer view platform for publishing worthy unpublished clinical and medical biology data and make it available to the scientific community free of charge. So the time has come to let your unpublished useful medical research data be published. Every researcher who currently has folders on their computer containing unpublished data should put this information in a publishable form and submit it to JUMD in order to make it visible, shared and or cited.

Tarek Shalaby

PERSONAL PROFILE

Dr. Tarek Shalaby is the founder and the Editor-in-Chief of the Journal of Unexplored Medical Data. Dr. Shalaby obtained his MD-PhD degree in molecular and cell biology at the University of Bern, Switzerland. He works at the Department of Oncology, University Children's Hospital, Zurich, Switzerland. Dr. Shalaby is dedicated to pediatric neuro-oncology research, and focuses on molecular genetics of children’s brain tumors. He is one of the founding members of the Swiss Pediatric Oncology Group (SPOG) tumor bank and the Childhood Liver Tumors Strategy Group- SIOPEL tumor bank.